Faculty Profile		
Name :	**Ms. Mansi Shah** (Assistant Professor, LJIP)	
Date of Birth :	**28/09/1989**	
Educational Qualifications:		
-Master's (University)	**M.Pharm. in Pharmacology, GTU (2011-2013)**	
-Bachelor's (University)	**B.Pharm., GU (2007-2011)**	
Area of Specialization:	**Pharmacology**	
Date of Joining (LJIP):	**01/01/2020**	
Present Position:	**Assistant Professor, L.J. Institute of Pharmacy**	
Contact Details:		
-Address :	**31/1, Jayant Park Society, Near Yamunaji Haveli, Opp. Vasishthnagar Post Office, Post Ghodasar, Ahmedabad – 380 050**	
-Email	**mansi.shah_ljip@ljinstitutes.edu.in**	
-Phone	**(M)** 9824846736	
Work Experience:	Teaching **(05 months)** , Industrial (**4.6 Years**)	
Subjects taught:		
-Under Graduate level	**Human Anatomy and Physiology (SEM-1 and SEM-2), Pathophysiology (SEM-3), Pharmacology (SEM-4, SEM-5, SEM-6, SEM-7, SEM-8)**	
Area of Specialization in your field	**Bioequivalence Study Of Cefixime 200 Mg And Dicloxacillin 500 Mg In Healthy Human Volunteers Under Fasting Condition**	
A brief account of work done in M. Pharm.	***"*Bioequivalence Study Of Cefixime 200 Mg And Dicloxacillin 500 Mg In Healthy Human Volunteers Under Fasting Condition*"*** An open label, balanced, randomized two-treatment, two-sequence, two-period, single dose, crossover bioavailability study of Cefixime 200 mg and Dicloxacillin 500 mg was conducted in 25 healthy volunteers under fasting condition. Among which 23 subjects had completed clinical phase. Eligible participants were randomly assigned in 1:1 ratio to receive single dose of Cefixime 200 mg and Dicloxacillin 500 mg. After an overnight fasting of at least 10 hours, single oral dose of Cefixime 200 mg and Dicloxacillin 500 mg either test or reference formulation in each period was administered with 240 ± 5 ml of drinking water at room temperature by trained personnel in each period.	

	A total of 28 blood samples were collected from each subject in K2EDTA vacutainers (containing K2EDTA as an anticoagulant) during each period. The venous blood samples 10 mL each was withdrawn at pre-dose (before dosing, at approximately –1.00 to -0.00 hrs) and 4 mL each at 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, 5.00, 5.33, 5.67, 6.00, 6.50, 7.00, 7.50, 8.00, 9.00, 10.00, 11.00, 12.00, 14.00, 18.00 and 24.00 hours after dosing. Concentration in plasma was analyzed by LC-MS/MS method. Cmax, AUC (0-t) and AUC (o-inf) for Cefixime and Dicloxacillin were evaluated. Safety was based on recording of adverse events, monitoring vital signs, ECGs and laboratory test at baseline and completion of study The Cmax, AUC (0-t) and AUC (o-inf) were analyzed using Analysis Of Variance and it was found that 90% confidence intervals were 81.99-122.89,81.03-123.59,81.28-123.12 for Cefixime and84.61-1156,82.46-105.9,82.45-105.26 for Dicloxacillin. Hence they were within the acceptance criteria of 80%-125% 90% confidence interval indicated that the Test Treatment (T) is bioequivalent to the Reference Treatment(R).
Summer/Winter/School/Conference/ Workshops attended:	**03**

Conferences ,Workshops and Seminars

1. **Poster presentation**: Risk of Cancer increases in woman undergoing *in-vitro* fertilization at Pharmanext Conference in 2012
2. **Attended Conference** on "Novel Technologies to Expedite Drug Discovery and Development" at Saraswati Institute of Pharmacy in 2011
3. **Attended Conference** on "Innovations in Biotechnology: From Education to Industry" in 2012.

Notable Achievements and activity executed:

- **Passed GPAT examination with ALL INDIA RANK 3826** in 2011 and **got JRF of Rs. 8,000/-** per month from AICTE for two consecutive years.